Subscribe for email alerts

Don’t miss a single Science & Enterprise post. Sign up for our daily email alerts.

Donate to Science & Enterprise

Please share Science & Enterprise

GSK Acquires Advanced Vaccine Biotech in $3.3B Deal

Streptococcus pneumoniae bacteria

Drug maker GSK is buying a biotechnology company developing vaccines for respiratory and infectious diseases that generate multiple immune responses. . . . → Read More: GSK Acquires Advanced Vaccine Biotech in $3.3B Deal

Partnership Developing Faster, Sensitive Covid-19 Test

SARS-CoV-2 and cell

A collaboration between developers of protein analytics and test-strip diagnostics aims to create a quicker, more sensitive, easy-to-use Covid-19 detection test. . . . → Read More: Partnership Developing Faster, Sensitive Covid-19 Test

Digital Mental Therapy Company to Go Public in Merger

Child with computer tablet

A creator of game therapies for cognitive impairments is becoming a publicly-traded company through a special purpose acquisition company or SPAC. . . . → Read More: Digital Mental Therapy Company to Go Public in Merger

Novo Nordisk Buys RNA Biotech in $3.3B Deal

Wall Street sign

Global drug maker Novo Nordisk is acquiring biotechnology company Dicerna Pharmaceuticals Inc. in an all-cash deal valued at $3.3 billion. . . . → Read More: Novo Nordisk Buys RNA Biotech in $3.3B Deal

Synthetic Antibody Company Goes Public in $230M Merger

Four fist bump

A developer of synthetic antibodies for inflammatory and skin disorders is becoming a public company through a special purpose acquisition-merger. . . . → Read More: Synthetic Antibody Company Goes Public in $230M Merger

RNA Manufacturer Goes Public in $282M Merger

Bumble bee and flower

A company producing synthetic RNA for agricultural and biomedical applications is now a public company after a special-purpose acquisition. . . . → Read More: RNA Manufacturer Goes Public in $282M Merger

Protein Chemistry Biotech Acquired in $2B Deal

DNA analysis graphic

Drug maker Bayer is acquiring a company discovering new therapies with a technology that reveals complex protein targets considered difficult to address. . . . → Read More: Protein Chemistry Biotech Acquired in $2B Deal

Sanofi Acquires mRNA Developer in $3.2B Deal

Wall Street sign

Drug maker Sanofi is purchasing biotechnology company Translate Bio, a developer of messenger RNA vaccines and therapies, and a long-time collaborator. . . . → Read More: Sanofi Acquires mRNA Developer in $3.2B Deal

Neuro Disease Start-Up Raises $73M in Early Funds

Nerve cells illustration

A new enterprise discovering treatments for neurodegenerative diseases is merging with another start-up and raising $73 million its first venture round. . . . → Read More: Neuro Disease Start-Up Raises $73M in Early Funds

Synthetic Bio Company Goes Public in $2.5B Merger

Investment graphic

A company developing synthetic biology and engineering tools for biotechnology is becoming a public company through a special-purpose acquisition. . . . → Read More: Synthetic Bio Company Goes Public in $2.5B Merger